01.22.26 -- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26

Explore how modern manufacturing software is transforming operations with AI-driven insights to empower CDMOs and CMOs to boost efficiency, agility, and client satisfaction in a competitive landscape.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Here, we identify twelve critical CMC challenges that frequently threaten cell therapy development programs and provide practical strategies to overcome them.

Find out how genome engineering and iPSCs are being used to curb critical challenges of durability and host immune clearance in both clinical and preclinical settings for allogeneic cell therapies.

Resilience is the bridge to patient access. Discover how to design your logistics with intentional flexibility to withstand real-world disruptions and protect product integrity under pressure.

Reducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.

Learn from this incident the importance of investing in reliable, real-time environmental monitoring systems that proactively address operational vulnerabilities and ensure patient safety.

Watch how this science-driven and digitally structured approach reduced onboarding timelines for gene therapy from 12 months to just 3, setting a new benchmark in technology transfers.